Avalo Therapeutics, Inc. (AVTX) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "AVTX"
      ],
      "issuer_cik": "0001534120",
      "owner_cik": "0001810417",
      "accession_number": "0001810417-26-000023",
      "form_type": "4",
      "filing_date": "2026-09-18",
      "period_of_report": "2026-09-16",
      "issuer_name": "Avalo Therapeutics, Inc.",
      "issuer_trading_symbol": "AVTX",
      "owner_name": "Sullivan Christopher Ryan",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Financial Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-09-16",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 12394,
      "transaction_price_per_share": 16.3335,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 39900,
      "transaction_value": 202437.399,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."
        },
        {
          "id": "F2",
          "description": "The reported securities were sold in multiple transactions at prices ranging from $15.91 to $16.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."
        }
      ]
    },
    {
      "tickers": [
        "AVTX"
      ],
      "issuer_cik": "0001534120",
      "owner_cik": "0001810417",
      "accession_number": "0001810417-26-000021",
      "form_type": "4",
      "filing_date": "2026-09-11",
      "period_of_report": "2026-09-10",
      "issuer_name": "Avalo Therapeutics, Inc.",
      "issuer_trading_symbol": "AVTX",
      "owner_name": "Sullivan Christopher Ryan",
      "is_director": false,
      "is_officer": true,
      "is_ten_percent_owner": false,
      "is_other": false,
      "officer_title": "Chief Financial Officer",
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": true,
      "transaction_date": "2026-09-10",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 10185,
      "transaction_price_per_share": 17.6197,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 39900,
      "transaction_value": 179456.64450000002,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F1",
          "description": "These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."
        },
        {
          "id": "F2",
          "description": "The reported securities were sold in multiple transactions at prices ranging from $17.17 to $17.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.